Information Provided By:
Fly News Breaks for April 15, 2015
CMRX
Apr 15, 2015 | 08:48 EDT
After BARDA posted an intent to award notice for a sole source contract to Chimerix for brincidofovir for smallpox, Brean Capital noted that the award will post for 15 days to verify that no other sources can meet this requirement. The firm noted the notice includes strong, positive language in support of brincidofovir and it believes Chimerix should "easily win" the deal, which could be worth $435M if the full 1.7M treatment courses are ordered. Brean has a Buy rating and $45 price target on Chimerix.
News For CMRX From the Last 2 Days
There are no results for your query CMRX